Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Health Czar DeParle Brings Medicare, Business Bona Fides To White House

This article was originally published in The Gray Sheet

Executive Summary

With the appointment of former Medicare chief Nancy-Ann DeParle to head up the White House Office of Health Care Reform, President Obama has tapped someone who not only has deep budget and Medicare/Medicaid knowledge, but is also at ease in device company boardrooms and experienced with health industry private equity deals

You may also be interested in...



People In Brief

Administration reform post: Michael Hash, a former deputy administrator at the Health Care Financing Administration (now CMS), has joined the administration in a top-level role in health care reform. Hash's responsibilities will include coordinating reform activities between the White House Office of Health Reform and the Department of Health and Human Services. Hash was most recently a principal at Health Policy Alternatives, a Washington-based consulting firm. He was at HCFA from 1998 to 2000 and served as deputy to Nancy-Ann DeParle, now director of the White House health reform office (1"The Gray Sheet" March 9, 2009, p. 9)

Parkinson’s Results Further Sweeten AbbVie’s Acquisition of Cerevel

Cerevel, which AbbVie is spending $8.7bn to acquire, unveiled topline results from the TEMPO-3 study of tavapadon, which an analyst said represents potentially a $1bn opportunity.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027187

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel